href="#ulink_0a9c48fb-33d3-58bd-ae36-78d23b51307d">6Houghton LA, Vieth R: The case against ergocalciferol (vitamin D2) as a vitamin supplement. Am J Clin Nutr 2006;84:694–697.
7Hollis BW: Comparison of equilibrium and disequilibrium assay conditions for ergocalciferol, cholecalciferol and their major metabolites. J Steroid Biochem 1984;21:81–86.
8Horst RL, Reinhardt TA, Ramberg CF, Koszewski NJ, Napoli JL: 24-Hydroxylation of 1,25-dihydroxyergocalciferol. An unambiguous deactivation process. J Biol Chem 1986;261:9250–9256.
9Zhu JG, Ochalek JT, Kaufmann M, Jones G, Deluca HF: CYP2R1 is a major, but not exclusive, contributor to 25-hydroxyvitamin D production in vivo. Proc Natl Acad Sci U S A 2013;110:15650–15655.
10Moghadasian MH: Cerebrotendinous xanthomatosis: clinical course, genotypes and metabolic backgrounds. Clin Invest Med 2004;27:42–50.
11Cheng JB, Motola DL, Mangelsdorf DJ, Russell DW: De-orphanization of cytochrome P450 2R1: a microsomal vitamin D 25-hydroxilase. J Biol Chem 2003;278:38084–38093.
12Cheng JB, Levine MA, Bell NH, Mangelsdorf DJ, Russell DW: Genetic evidence that the human CYP2R1 enzyme is a key vitamin D 25-hydroxylase. Proc Natl Acad Sci U S A 2004;101:7711–7715.
13Bikle D: Extra Renal Synthesis of 1,25-Dihydroxyvitamin D and its Health Implications; in Holick M (ed): Vitamin D: Physiology, Molecular Biology, and Clinical Applications. Humana Press 2010, pp 277–295.
14Bikle DD, Rasmussen H: The ionic control of 1,25-dihydroxyvitamin D3 production in isolated chick renal tubules. J Clin Invest 1975;55:292–298.
15Bikle DD, Murphy EW, Rasmussen H: The ionic control of 1,25-dihydroxyvitamin D3 synthesis in isolated chick renal mitochondria. The role of calcium as influenced by inorganic phosphate and hydrogen-ion. J Clin Invest 1975;55:299–304.
16Bikle DD: Extra renal synthesis of 1,25 dihydroxyvitamin D and its Health Implications. Clin Rev Bone Min Metab 2009;7:114–125.
17Bikle DD, Pillai S, Gee E, Hincenbergs M: Tumor necrosis factor-alpha regulation of 1,25-dihydroxyvitamin D production by human keratinocytes. Endocrinology 1991;129:33–38.
18Bikle DD, Pillai S, Gee E, Hincenbergs M: Regulation of 1,25-dihydroxyvitamin D production in human keratinocytes by interferon-gamma. Endocrinology 1989;124:655–660.
19Bikle DD, Nemanic MK, Gee E, Elias P: 1,25-Dihydroxyvitamin D3 production by human keratinocytes. Kinetics and regulation. J Clin Invest 1986;78:557–566.
20Gyetko MR, Hsu CH, Wilkinson CC, Patel S, Young E: Monocyte 1 alpha-hydroxylase regulation: induction by inflammatory cytokines and suppression by dexamethasone and uremia toxin. J Leukoc Biol 1993;54:17–22.
21St-Arnaud R, Messerlian S, Moir JM, Omdahl JL, Glorieux FH: The 25-hydroxyvitamin D 1-alpha-hydroxylase gene maps to the pseudovitamin D-deficiency rickets (PDDR) disease locus. J Bone Min Res 1997;12:1552–1559.
22Adams JS, Gacad MA: Characterization of 1 alpha-hydroxylation of vitamin D3 sterols by cultured alveolar macrophages from patients with sarcoidosis. J Exp Med 1985;161:755–765.
23Jones G, Prosser DE, Kaufmann M: 25-Hydroxyvitamin D-24-hydroxylase (CYP24A1): its important role in the degradation of vitamin D. Arch Biochem Biophys 2012;523:9–18.
24Sakaki T, Sawada N, Komai K, Shiozawa S, Yamada S, Yamamoto K, et al: Dual metabolic pathway of 25-hydroxyvitamin D3 catalyzed by human CYP24. Eur J Biochem 2000;267:6158–6165.
25Prosser DE, Kaufmann M, O’Leary B, Byford V, Jones G: Single A326G mutation converts human CYP24A1 from 25-OH-D3–24-hydroxylase into -23-hydroxylase, generating 1alpha,25-(OH)2D3–26,23-lactone. Proc Natl Acad Sci U S A 2007;104:12673–12678.
26Plachot JJ, Du Bois MB, Halpern S, Cournot-Witmer G, Garabedian M, Balsan S: In vitro action of 1,25-dihydroxycholecalciferol and 24,25- dihydroxycholecalciferol on matrix organization and mineral distribution in rabbit growth plate. Metab Bone Dis Relat Res 1982;4:135–142.
27Schlingmann KP, Kaufmann M, Weber S, Irwin A, Goos C, John U, et al: Mutations in CYP24A1 and idiopathic infantile hypercalcemia. N Eng J Med 2011;365:410–421.
28O’Keeffe DT, Tebben PJ, Kumar R, Singh RJ, Wu Y, Wermers RA: Clinical and biochemical phenotypes of adults with monoallelic and biallelic CYP24A1 mutations: evidence of gene dose effect. Osteoporosis Int 2016;27:3121–3125.
29Armbrecht HJ, Hodam TL, Boltz MA, Partridge NC, Brown AJ, Kumar VB: Induction of the vitamin D 24-hydroxylase (CYP24) by 1,25-dihydroxyvitamin D3 is regulated by parathyroid hormone in UMR106 osteoblastic cells. Endocrinology 1998;139:3375–3381.
30Reddy GS, Muralidharan KR, Okamura WH, Tserng KY, McLane JA: Metabolism of 1alpha,25-dihydroxyvitamin D(3) and its C-3 epimer 1alpha,25-dihydroxy-3-epi-vitamin D(3) in neonatal human keratinocytes. Steroids 2001;66:441–450.
31Bailey D, Veljkovic K, Yazdanpanah M, Adeli K: Analytical measurement and clinical relevance of vitamin D(3) C3-epimer. Clin Biochem 2013;46:190–196.
32Kamao M, Tatematsu S, Hatakeyama S, Sakaki T, Sawada N, Inouye K, et al: C-3 epimerization of vitamin D3 metabolites and further metabolism of C-3 epimers: 25-hydroxyvitamin D3 is metabolized to 3-epi-25-hydroxyvitamin D3 and subsequently metabolized through C-1alpha or C-24 hydroxylation. J Biol Chem 2004;279:15897–15907.
33Brown AJ, Ritter C, Slatopolsky E, Muralidharan KR, Okamura WH, Reddy GS: 1Alpha,25-dihydroxy-3-epi-vitamin D3, a natural metabolite of 1alpha,25-dihydroxyvitamin D3, is a potent suppressor of parathyroid hormone secretion. J Cell Biochem 1999;73:106–113.
34Carter GD, Jones JC, Shannon J, Williams EL, Jones G, Kaufmann M, et al: 25-Hydroxyvitamin D assays: potential interference from other circulating vitamin D metabolites. J Steroid Biochem Mol Biol 2015;164:134–138.